June 13, 2022 11:04 AM EDTUpdated 06:26 PM

Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data

John Carroll

Editor & Founder

Five years after Novartis made history with the approval of the first CAR-T, Kymriah, we’re getting a clearer picture of just how important the advance …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data

John Carroll

Editor & Founder

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

No­var­tis may still be grap­pling with Kym­ri­ah sales, but his­toric CAR-T promise still shines through 5-year da­ta

Editor & Founder

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data